PIXUVRI

This brand name is authorized in Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, United Kingdom

Active ingredients

The drug PIXUVRI contains one active pharmaceutical ingredient (API):

1 Pixantrone UNII P0R64C4CR9 - PIXANTRONE DIMALEATE

Pixantrone is a cytotoxic aza-anthracenedione. Unlike approved anthracyclines (doxorubicin and others) and anthracenediones (mitoxantrone), pixantrone is only a weak inhibitor of topoisomerase II. Pixantrone is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell lymphomas (NHL). Read about Pixantrone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PIXUVRI Powder for concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01DB11		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1582938
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 112764001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 422323
Country: FR	Base de données publique des médicaments	Identifier(s): 69454261
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 215169
Country: IT	Agenzia del Farmaco	Identifier(s): 042463012
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1066427
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100313180